comparemela.com

Latest Breaking News On - Australian stock exchange ath ax - Page 1 : comparemela.com

Alterity Therapeutics to Present New Data on ATH434 at the

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),.

United statesSan franciscoRemy bernardaDanielo claassenMargaret bradburyDavid stamlerDaniel claassenHannah howlettDepartment of pharmaceutical sciencesNonclinical developmentEuropean commissionAlterity therapeuticsWorld orphan drug congress united statesAmerican academy of neurologyWayne state universityNational institute of health

Alterity Therapeutics Receives a A$3 9 Million Research &

MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity”.

United statesSan franciscoDavid stamlerRemy bernardaHannah howlettAustralian taxation officeDevelopment tax incentiveAustralian government researchAlterity therapeuticsAlterity therapeutics limitedEuropean commissionTherapeutics limitedAustralian governmentMultiple system atrophyMultiple systemAustralian stock exchange ath ax

Alterity Therapeutics to Present New Data at the Upcoming

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to.

United statesSan franciscoDanielo claassenRemy bernardaHannah howlettDaniel claassenMargaret bradburyDavid stamlerEuropean commissionVanderbilt universityNational institute of healthParkinson foundationAmerican academy of neurologyAlterity therapeuticsInternational conferenceVanderbilt university medical center

Alterity Therapeutics Phase 2 Data Monitoring Committee

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,.

San franciscoUnited statesDavid stamlerRemy bernardaHannah howlettEuropean commissionAlterity therapeuticsDrug administrationData monitoring committeeLine data expectedChief executive officerMultiple system atrophySystem atrophyMedia contactsSecurities actAustralian stock exchange ath ax

Alterity Therapeutics Issues Shareholder Letter

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN.

San franciscoUnited statesDavid stamlerAlterity therapeuticsVanderbilt university medical centerEuropean commissionPreliminary dataMultiple system atrophyOrphan drug designationChief executive officerMultiple systemSecurities actAustralian stock exchange ath axAlterity therapeutics limitedAlterity therapeuticsMultiple system atrophy

vimarsana © 2020. All Rights Reserved.